How Does Health Technology Assessment of Personalized Medicine for Non-Small Cell Lung Cancer Differ in France, Germany, and England?
Abstract
Authors
A Sherwood L Mitrofan
A Sherwood L Mitrofan
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now